PhaseII/III study comparing trabectedin (T) versus T plus tTF-NGR to entrap T inside the tumor in patients with metastatic and/or refractory soft tissue sarcoma (STS, 2nd line)
Laufzeit: 01.01.2021 - 31.12.2026
imported
Kurzfassung
Unresectable or metastatic soft tissue sarcoma (STS) after failure of anthracycline-containing 1st line treatment or with contraindications to these drugs; CD13 positivity in central histology (grade >/= 1+)
ARM 1 Standard chemotherapy with Trabectidin (in-label)
ARM 2 Test product tTF-NGR added to standard Trabectedin
Plus CENTRALIZED LAB - HAFA sample (before dosing) and Pharmacokinetics tTF-NGR
Beteiligte Einrichtungen
